Eligo Bioscience–Grienenberger A: management, 201909– CBO before Sanofi Global Business Development

	Period	2019-09-17
	Organisation	Eligo Bioscience S.A.
	Organisation 2	Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
	Group	Sanofi (Group) [since May 2011]
	Product	microbiomics
	Product 2	EB003 (Eligo Bioscience)
	Person	Grienenberger, Aurélie (Eligo Bioscience 201909– CBO before Sanofi Global Business Development)

Eligo Bioscience S.A.. (9/17/19). "Press Release: Eligo Bioscience Strengthens Its Leadership and Development Team". Paris.

Company appoints Aurélie Grienenberger, PhD, as Chief Business Officer and Olivier Kerbarh, PhD, as Senior Manager CMC.

Eligo Bioscience SA, a biotechnology company developing next-generation precision medicines for microbiome engineering, today announced the expansion of the Company’s executive management team and development team. Aurélie Grienenberger, PhD, has been appointed Chief Business Officer and Olivier Kerbarh, PhD, has been appointed Senior Manager CMC.

“We are tremendously excited to add these two deeply experienced individuals to our growing team at Eligo Bioscience at a time when we are moving our lead program towards the clinic.”, said Xavier Duportet, co-founder and CEO at Eligo Bioscience. “We look forward to their unique and comprehensive expertise as we grow the organization to best position our programs for the clinic and pursue strategic opportunities to strengthen our pipeline. Their collective experience will be invaluable as we execute on our strategy to discover and develop next-wave microbiome precision medicines for patients with diseases for which limited treatment options currently exist.”

—

Aurélie Grienenberger brings substantial experience in business development and drug development. She joins Eligo from Sanofi Global Business Development, where her focus was on executing collaboration and licensing deals to support Sanofi R&D pipeline across immunology, rare diseases, metabolic diseases, vaccines and infectious diseases. In particular, she was deeply involved in the strategic transaction with Evotec to accelerate Infectious Diseases R&D. Previously, Aurelie acquired strategic and operational R&D expertise in biotech and pharma, over 15+ years. She held Development and Regulatory leadership positions, supporting programs ranging from Phase 1 to FDA approval at Dyax Corp. and Fovea Pharmaceuticals, and served as Chief of Staff to the President of R&D at Sanofi. Aurélie holds an engineering degree from Ecole Polytechnique with a major in Chemistry and Biology, a PhD from the University of Marseilles in genetics and molecular biology, and a Business Master from London Business School.

Olivier Kerbarh brings 13 years of experience in biotech drug development, especially in CMC. He joined the biotech industry by working first during 6 years for Endotis Pharma in Paris (France), where he participated in the preclinical development of the synthetic anticoagulant EP217609 and its specific antidote avidin. Both molecules were developed up to Phase II for extracorporeal circulation in cardiac surgery. After this, he worked for 6 years for the biotech DBV Technologies in Montrouge (France), a company specialized in the development of ViaskinÒ patches to treat food allergy by epicutaneous immunotherapy. As a Pharmaceutical Development Manager and Project Leader, he participated to the development of ViaskinÒ products from preclinical to Phase III. Olivier holds a PhD degree in Biochemistry from the University of Nottingham (UK). After that, he specialized in enzymology as post-doctoral research associate by joining some of the top labs in this discipline at the Universities of Edinburgh and Cambridge (UK).

Eligo Bioscience’s EligobioticsTM: a unique platform

EligobioticsTM platform enables the production of DNA delivery vectors derived from phage-like particles that can be used to delivery therapeutic payloads to targeted bacterial populations in the microbiome. Eligo Bioscience’s EligobioticsTM platform has generated a pipeline of four programs, of which the first three are based on the delivery of a nuclease system targeting pathogenic or antibiotic-resistance genetic signatures in gut and skin bacterial species, leading to the specific eradication of the bacterial strains carrying these genetic signature while leaving the rest of the commensal strains intact. The fourth program is based on the delivery of a non-lethal therapeutic payload in the targeted bacterial populations.

—

About Eligo Bioscience

Eligo Bioscience is a next-generation microbiome precision medicine company. Eligo Bioscience is pioneering the development of phage-derived DNA delivery vectors for microbial species involved in a number of diseases areas, including infectious diseases, inflammatory diseases and auto-immune diseases. Eligo Bioscience is a VC-backed company (Khosla Ventures and Seventure Partners) and was founded by David Bikard, PhD, Luciano Marraffini, PhD, Timothy Lu, MD-PhD and Xavier Duportet, PhD. For more information please visit www.eligo.bio.

Contact: contact@eligo.bio